Paolo Tarantino: The ratio of enrollment to industry-sponsored trials has doubled between 2008-2022

Paolo Tarantino shared the following on X:

“Out in JCO: the ratio of enrollment to Industry- vs Federally-sponsored trials doubled between 2008-2022. This led to an acceleration in drug development, but fewer trials exploring de-escalation or non-drug-related questions. Great editorial by Yousef Abdou.”

Sarah Sammons reposted this post, adding the following:

“In the US, there is a growing reliance on industry to conduct cancer clinical research. Underinvestment in federally sponsored research comes at a cost for patients and researchers, with lost opportunities for scientific and population advances. I feel this deeply every day.

Industry plays a critical role in oncology advancement but they usually cannot address questions unrelated to their assets/drugs. There is so much more to do to advance oncology care outside of drug development.”

Patient Enrollment to Industry-Sponsored Versus Federally Sponsored Cancer Clinical Trials

Authors:  Joseph M. Unger, Hong Xiao, Riha Vaidya, Michael LeBlanc.

Source: Paolo Tarantino/X and Sarah Sammons/X

More posts featuring Paolo Tarantino on oncodaily.com

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.

Sarah Sammons is a medical oncologist at Dana-Farber’s Breast Oncology Center specializing in treating patients with all stages of breast cancer. She is particularly focusing on improving outcomes for those with metastatic breast cancer. Through leading numerous clinical trials, she has developed new treatment options for breast cancer patients. Additionally, Dr. Sammons is skilled in treating brain metastases.